EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
3.1.1.23 | Colitis |
25912803 |
The monoacylglycerol lipase inhibitor JZL184 decreases inflammatory response in skeletal muscle contusion in rats. |
causal interaction therapeutic application unassigned |
4 4 0 |
3.1.1.23 | Colitis |
28079617 |
Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review. |
causal interaction therapeutic application unassigned |
4 1 0 |
3.1.1.23 | Endometrial Neoplasms |
31357249 |
Effect of monoacylglycerol lipase on the tumor growth in endometrial cancer. |
causal interaction ongoing research unassigned |
3 3 0 |
3.1.1.23 | Glaucoma |
30446439 |
Synthesis and evaluation of potent and selective MGL inhibitors as a glaucoma treatment. |
causal interaction therapeutic application unassigned |
3 4 0 |
3.1.1.23 | Neoplasms |
24676249 |
Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. |
causal interaction therapeutic application unassigned |
3 3 0 |
3.1.1.23 | Neoplasms |
27809504 |
Structural Optimization of 4-Chlorobenzoylpiperidine Derivatives for the Development of Potent, Reversible, and Selective Monoacylglycerol Lipase (MAGL) Inhibitors. |
causal interaction therapeutic application unassigned |
3 4 0 |
3.1.1.23 | Neoplasms |
29962341 |
Development of thiazole-5-carboxylate derivatives as selective inhibition of monoacylglycerol lipase as a target in Cancer. |
causal interaction therapeutic application unassigned |
3 4 0 |
3.1.1.23 | Neoplasms |
30696302 |
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors. |
causal interaction therapeutic application unassigned |
3 4 0 |
3.1.1.23 | Neoplasms |
32322464 |
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. |
causal interaction unassigned |
3 0 |
3.1.1.23 | Neurodegenerative Diseases |
30354159 |
Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders. |
causal interaction therapeutic application unassigned |
3 1 0 |